Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 14/20 | 0.67 |
| ▸ | LIG1 | P18858 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | TAAR5 | O14804 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124480 | 0.88 | PCNA (0.63) | PCNALIG1TAAR5TAAR1 | |
| SCHEMBL14264009 | 0.84 | THRB (0.68) | PCNAPOLBTHRATHRBMAPK1 | |
| SCHEMBL13886598 | 0.84 | TAAR5 (0.68) | PCNALIG1POLBTHRATHRB | |
| SCHEMBL22382794 | 0.84 | PCNA (0.67) | PCNALIG1POLBTHRATHRB | |
| SCHEMBL14264006 | 0.83 | THRB (0.62) | PCNALIG1POLBTHRATHRB | |
| SCHEMBL15500034 | 0.82 | PCNA (0.77) | PCNALIG1POLBTHRATHRB | |
| SCHEMBL4005004 | 0.81 | PCNA (0.66) | PCNALIG1POLBTHRATHRB | |
| SCHEMBL16124470 | 0.80 | PCNA (0.82) | PCNAPOLBTHRATHRBMAPK1 | |
| 3,5-Diiodothyropropionic Acid SCHEMBL1501771 | 0.80 | PCNA (1.00) | PCNALIG1POLBTHRATHRB | |
| SCHEMBL14230070 | 0.80 | PCNA (0.62) | PCNALIG1POLBTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-09-25 | — | — | US | disclosed |
| US-8507639-B2 | Polyamide block polymers containing iodoarylcarboxyl pendant groups and modified poly(meth)acrylamide; coupling; for tracking movement of a catheter through the body or inflation of balloon at site | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20080064848-A1 | Radiopaque amide polymers and medical devices formed thereof | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288077-A1 | SUBSTITUTED 4-PHENOXYPHENOL ANALOGS AS MODULATORS OF PROLIFERATING CELL NUCLEAR ANTIGEN ACTIVITY | MKI67, PCNA, PCLAF | PCNA 2/4885LIG1 1098/4885POLB 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.